Abstract
The National Institute of Health and Care Research Innovation Observatory undertook a pipeline analysis to deliver insight needed to support decisions about the reality and impact of adopting license extensions for three immuno-oncology medicines, supporting decision making within NHS England. This project aimed to provide a robust horizon scan of three specified immune-oncology medicines and their indications in clinical development, supporting operational preparation and efficiency in topic selection, and assist indication-based pricing through a strategic policy lens.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
